We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare
On track for full commercial launch in the U.S. in late June CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 14, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019 , the Compensation Committee of Sage’s Board of
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 40 th Annual Global Healthcare
CAMBRIDGE, Mass --(BUSINESS WIRE)--May 14, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2019-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on May 1, 2019 , the Compensation Committee of Sage’s Board of
ZULRESSO™ (brexanolone) injection approved by U.S. FDA and on track for launch in late June Commercial team is launch ready; field teams focusing on payer engagement and identifying pathways to care Strong financial position with ~$1.4B in cash Milestones anticipated throughout 2019 in clinical
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on April 1, 2019 , the Compensation Committee of Sage’s
